Xiaoyong Lu
Xiaoyong Lu is a seasoned professional in the field of genetic medicine, currently serving as the Director of Oligonucleotide at Eli Lilly and Company since June 2023. Based in Indianapolis, Indiana, he leads innovative initiatives in oligonucleotide and genetic medicine, leveraging his extensive expertise in RNA delivery systems and oligonucleotide synthesis.
Before joining Eli Lilly, Xiaoyong held various significant roles at Sirnaomics, where he spent over six years. As the Director of Chemistry & RNA Target Delivery from January 2021 to June 2023, he led a team of chemists and biologists in pioneering RNA drug delivery technologies and managed the oligonucleotide synthesis lab. His responsibilities included designing and screening siRNA sequences, overseeing chemical modifications, and scaling up the manufacture of oligonucleotides and peptides.
Xiaoyong's tenure at Sirnaomics also saw him as a Group Leader in Novel RNA Delivery, Formulation, and CMC practice, and as a Senior Scientist specializing in Drug Delivery, Nanoparticle Formulation, and Oligonucleotide Synthesis. His contributions were pivotal in developing siRNA targeting delivery systems and formulating nanoparticle-based siRNA drug composites.
In addition to his industry roles, Xiaoyong is a member of the Cheeky Scientist Association, where he has been active since January 2017. This professional association focuses on enhancing communication skills and social intelligence among its members.
Xiaoyong holds a Cheeky Scientist Industry Trained Certificate, further underscoring his commitment to continuous professional development and industry excellence.